Cue Biopharma (NASDAQ:CUE) Rating Increased to Buy at Wall Street Zen

Cue Biopharma (NASDAQ:CUE) was upgraded by stock analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Saturday.

Separately, Weiss Ratings upgraded shares of Cue Biopharma from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, May 18th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock has a consensus rating of “Sell”.

Cue Biopharma Trading Down 0.6%

Shares of NASDAQ CUE opened at $29.46 on Friday. The firm has a 50 day moving average of $156.55 and a 200 day moving average of $270.49. The firm has a market capitalization of $123.73 million, a price-to-earnings ratio of -5.28 and a beta of 2.52. Cue Biopharma has a 12-month low of $4.97 and a 12-month high of $41.42.

Cue Biopharma (NASDAQ:CUE) last announced its earnings results on Thursday, May 14th. The company reported ($1.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.30) by $2.22. The company had revenue of $5.69 million during the quarter, compared to analyst estimates of $2.50 million. Cue Biopharma had a negative net margin of 59.65% and a negative return on equity of 98.30%.

Hedge Funds Weigh In On Cue Biopharma

Hedge funds have recently modified their holdings of the company. Boothbay Fund Management LLC bought a new position in shares of Cue Biopharma in the third quarter worth approximately $439,000. Stifel Financial Corp boosted its position in shares of Cue Biopharma by 25.4% in the fourth quarter. Stifel Financial Corp now owns 246,556 shares of the company’s stock worth $75,000 after purchasing an additional 50,000 shares during the period. Squarepoint Ops LLC bought a new position in shares of Cue Biopharma in the third quarter worth approximately $62,000. Northwestern Mutual Wealth Management Co. boosted its position in shares of Cue Biopharma by 730.0% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 83,000 shares of the company’s stock worth $57,000 after purchasing an additional 73,000 shares during the period. Finally, Texas Capital Bank Wealth Management Services Inc boosted its position in shares of Cue Biopharma by 1,231.2% in the fourth quarter. Texas Capital Bank Wealth Management Services Inc now owns 440,670 shares of the company’s stock worth $135,000 after purchasing an additional 407,568 shares during the period. 35.04% of the stock is currently owned by institutional investors.

Cue Biopharma Company Profile

Cue Biopharma is a clinical‐stage biotechnology company focused on the development of next‐generation immunotherapies for cancer and infectious diseases. The company’s proprietary platform, known as Cytokine Release & Targeting (CRT), is designed to deliver cytokine payloads directly to antigen‐specific T cells in order to enhance immune responses within targeted tissues. This approach aims to improve the therapeutic index of cytokine treatments by limiting systemic exposure and potentiating localized immune activation.

Founded in 2015 and headquartered in Cambridge, Massachusetts, Cue Biopharma has advanced multiple lead programs into early‐stage clinical studies.